Pertinax Pharma are delighted to announce that they have secured funding from Innovation 4 Growth (I4G). I4G is a funding scheme managed by the University of the West of England and developed using the European Regional Development Fund. It supports SMEs in the West of England to develop innovative products, technologies, processes and services.
Pertinax will use the I4G funding to support development of a new generation of aerosol sprays, which provide a resilient, tenacious, antimicrobial coating to treat wound and skin infections. CEO Dr Michele Barbour said “This new generation of aerosol sprays represents a very exciting step forward for us, and we are delighted that I4G have chosen to reward this innovation with funding. We anticipate that the first use of these sprays will be in the veterinary field, and our first priority is to test them in relation to treating foot disease in cattle. Digital dermatitis is a highly infectious foot condition which causes suffering and pain to the animal as well as representing an economic burden to the farmer. It is commonly treated using antibiotics, and the use of antibiotics in farm environments is recognised to drive the evolution of antibiotic-resistant bacteria. Our new sprays will have superior efficacy, resisting environmental challenges, while replacing antibiotics with our proprietary antiseptic technology.”
Pertinax are collaborating with leading academics Professor David Barrett and Dr Jim Spencer in the University of Bristol’s Faculties of Health and Life Sciences respectively, to advance and validate this technology. It is anticipated that the spray will find application in the treatment of other conditions, in veterinary and potentially human medicine, in the future.